Discover how oncology nurses can make a profound impact beyond the bedside by registering as stem cell and bone marrow donors to save lives.

Chasity Washington MPH, CHES | Authors | Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

Beth Eaby-Sandy is a thoracic oncology nurse practitioner in the Abramson Cancer Center at the University of Pennsylvania. She speaks nationally on the topics of lung cancer and supportive care ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.

NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.

The FDA approved zidesamtinib for metastatic ROS1-positive NSCLC following prior kinase inhibitor therapy, offering hope for patients with resistance. The US Food and Drug Administration (FDA) has ...

Stephanie Desrosiers discusses strategies for oncology nurses to manage chemotherapy shortages, ensuring patient safety, ...

NATCO Pharma receives tentative U.S. FDA approval for a generic version of the PARP inhibitor olaparib (Lynparza) for oncology indications. The U.S. Food and Drug Administration (FDA) has granted ...

Linda Casey, RN, shares essential strategies for oncology nurses to protect vulnerable patients from the clinical risks of wildfire smoke exposure. As Canadian wildfire smoke blanketed the tri-state ...

The Food and Drug Administration (FDA) has approved gedatolisib (Revtorpyk) for use in combination with fulvestrant, with or without palbociclib. This approval specifically targets adult patients with ...

The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progression. The Food and Drug Administration (FDA) has converted ...